Can intranasal drug use reduce HCV infection among injecting drug users?

Drug and Alcohol Dependence

Volumn 119, Issue 3, 2011, Pages 201-206

  Des Jarlais, Don C ^a   Hagan, Holly ^b   Arasteh, Kamyar ^a   McKnight, Courtney ^a   Semaan, Salaam ^c   Perlman, David C ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

HCV; Injecting; Intranasal drug use; Non injecting

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG ABUSE; DRUG DETOXIFICATION; ETHNICITY; FEMALE; HEPATITIS C; HUMAN; INFECTION RISK; INJECTION DRUG ABUSE; INTRANASAL DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK REDUCTION; SEROPREVALENCE; STRUCTURED INTERVIEW;

ADMINISTRATION, INTRANASAL; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HEROIN; HUMANS; MALE; QUESTIONNAIRES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

HEPATITIS C VIRUS;

EID: 82555167121     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.06.020     Document Type: Article

References (35)

1. Bridge J. Route transition interventions: potential public health gains from reducing or preventing injecting. Int. J. Drug Policy 2010, 21:125-128.
2. Burke K.P., Cox A.L. Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol. Res. 2010, 47:216-227.
3. Buster M., Witteveen E., Prins M., van Ameijden E., Schippers G., Krol A. Transitions in drug use in a new generation of problem drug users in Amsterdam: a 6-year follow-up study. Eur. Addict. Res. 2009, 15:179-187.
4. de la Fuente L., Barrio G., Royuela L., Bravo M. The transition from injecting to smoking heroin in three Spanish cities. Addiction 1997, 92:1749-1763.
5. Des Jarlais D., Arasteh K., McKnight C., Hagan H., Perlman D., Friedman S. Using hepatitis C virus and herpes simplex virus-2 to track HIV among injecting drug users in New York City. Drug Alcohol Depend. 2009, 101:88-91.
6. Des Jarlais D., Arasteh K., Perlis T., Hagan H., Abdul-Quader A., Heckathorn D., McKnight C., Bramson H., Nemeth C., Torian L., Friedman S. Convergence of HIV seroprevalence among injecting and non-injecting drug users in New York City: a new stage in a very large HIV epidemic. AIDS 2007, 21:231-235.
7. Des Jarlais D.C., Arasteh K., Perlis T., Hagan H., Heckathorn D.D., McKnight C., Bramson H., Friedman S.R. The transition from injection to non-injection drug use: long-term outcomes among heroin and cocaine users in New York City. Addiction 2007, 102:778-785.
8. Des Jarlais D.C., Casriel C., Friedman S.R., Rosenblum A. AIDS and the transition to illicit drug injection: results of a randomized trial prevention program. Br. J. Addict. 1992, 87:493-498.
9. Des Jarlais D.C., Perlis T., Arasteh K., Torian L.V., Hagan H., Beatrice S., Smith L., Wethers J., Milliken J., Mildvan D., Yancovitz S., Friedman S.R. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS 2005, 19(Suppl. 3):S20-S25.
10. Deuffic-Burban S. Expected increase in prevalence of HCV-related cirrhosis and its complications in the United States: no effect of current antiviral treatment coverage?. Gastroenterol. Clin. Biol. 2010, 34:577-579.
11. Dolan K., Clement N., Rouen D., Rees V., Shearer J., Wodak A. Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs?. Drug Alcohol Rev. 2004, 23:281-286.
12. Gerberding J.L. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: final report from a longitudinal study. J. Infect. Dis. 1994, 170:1410-1417.
13. Gillies M., Palmateer N., Hutchinson S., Ahmed S., Taylor A., Goldberg D. The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review. BMC Public Health 2010, 10:721.
14. Gossop M., Stewart D., Marsden J., Kidd T., Strang J. Changes in route of drug administration among continuing heroin users: outcomes 1 year after intake to treatment. Addict. Behav. 2004, 29:1085-1094.
15. Grebely J., Dore G.J. Hepatitis C: enhancing treatment for hepatitis C among drug users. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:11-13.
16. Grebely J., Thomas D.L., Dore G.J. HCV reinfection studies and the door to vaccine development. J. Hepatol. 2009, 51:628-631.
17. Hagan H., Des Jarlais D., Stern R., Lelutiu-Weinberger C., Scheinmann R., Strauss S., Flom P. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection. Int. J. Drug Policy 2007, 18:341-351.
18. Hagan H., McGough J.P., Thiede H., Hopkins S.G., Weiss N.S., Alexander E.R. Volunteer bias in nonrandomized evaluations of the efficacy of needle-exchange programs. J. Urban Health 2000, 77:103-112.
19. Hagan H., Pouget E., Des Jarlais D., Lelutiu-Weinberger C. Meta-regression of hepatitis C virus (HCV) infection in relation to time since onset of illicit drug injection: the influence of time and place. Am. J. Epidemiol. 2008, 168:1099-1109.
20. Hagan H., Pouget E.R., Williams I.T., Garfein R.L., Strathdee S.A., Hudson S.M., Latka M.H., Ouellet L.J. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J. Infect. Dis. 2010, 201:378-385.
21. Hagan H., Pouget R., Des Jaralis D. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J. Infect. Dis. 2011, 204:74-83.
22. Hagan H., Thiede H., Weiss N.S., Hopkins S.G., Duchin J.S., Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am. J. Public Health 2001, 91:42-46.
23. Highfield D., Schwartz R., Jaffe J., O'Grady K. Intravenous and intranasal heroin-dependent treatment-seekers: characteristics and treatment outcome. Addiction 2007, 102:1816-1823.
24. Hunt N., Griffiths P., Southwell M., Stillwell G., Strang J. Preventing and curtailing injecting drug use: a review of opportunities for developing 'route transition interventions'. Drug Alcohol Rev. 1999, 18:441-451.
25. Hunt N., Stillwell G., Taylor C., Griffiths P. Evaluation of a brief intervention to prevent initiation into injecting drugs. Educ. Prev. Policy 1998, 5:185-193.
26. Lucidarme D., Bruandet A., Ilef D., Harbonnier J., Jacob C., Decoster A., Delamare C., Cyran C., Van Hoenacker A.F., Fremaux D., Josse P., Emmanuelli J., Le Strat Y., Desenclos J.C., Filoche B. Incidence and risk factors of HCV and HIV infections in a cohort of intravenous drug users in the North and East of France. Epidemiol. Infect. 2004, 132:699-708.
27. Maher L., Jalaludin B., Chant K.G., Jayasuriya R., Sladden T., Kaldor J.M., Sargent P.L. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Addiction 2006, 101:1499-1508.
28. Mateu-Gelabert P., Maslow C., Flom P.L., Sandoval M., Bolyard M., Friedman S.R. Keeping it together: stigma, response, and perception of risk in relationships between drug injectors and crack smokers, and other community residents. AIDS Care 2005, 17:802-813.
29. Schottenfeld R.S., O'Malley S., Abdul-Salaam K., O'Connor P.G. Decline in intravenous drug use among treatment-seeking opiate users. J. Subst. Abuse Treat. 1993, 10:5-10.
30. Semaan S., Des Jarlais D.C., Malinowska-Sempruch K., Kirby A., Sharpe T.T. Human rights and HIV prevention among drug users. Right-Based Approaches to Public Health 2011, Springer Publishing Company, New York. E. Beracochea, C. Weinstein, D.P. Evans (Eds.).
31. Semaan S., Leinhos M. The ethics of public health practice for the prevention and control of sexually transmitted diseases. Behavioral Interventions for Prevention and Control of Sexually Transmitted Diseases 2007, 517-548. Springer-SBM, New York. S. Aral, J. Douglas, J. Lipshutz (Eds.).
32. Stoove M.A., Gifford S.M., Dore G.J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend. 2005, 77:81-86.
33. USAID, 2007. USAID Funded Drug Demand Reduction Program in Uzbekistan, Tajikistan and the Ferghana Valley of Kyrgyzstan. (accessed 17.10.07). http://www.ddrprogram.org/newsletter_eng.pdf.
34. van den Berg C.H., Smit C., Bakker M., Geskus R.B., Berkhout B., Jurriaans S., Coutinho R.A., Wolthers K.C., Prins M. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur. J. Epidemiol. 2007, 22:183-193.
35. Wood E., Lloyd-Smith E., Li K., Strathdee S., Small W., Tyndall M., Montaner J., Kerr T. Frequent needle exchange use and HIV incidence in Vancouver, Canada. Am. J. Med. 2007, 120:172-179.